Novel lung imaging biomarkers and skin gene expression subsetting in dasatinib treatment of systemic sclerosis-associated interstitial lung disease

g:Profiler—a web server for functional interpretation of gene lists (2016 update)

(2016) Jüri Reimand et al.   NUCLEIC ACIDS RESEARCH

Dasatinib Reduces Lung Inflammation and Fibrosis in Acute Experimental Silicosis

(2016) Fernanda Ferreira Cruz et al.   PLoS One

Dasatinib blocks transcriptional and promigratory responses to transforming growth factor-beta in pancreatic adenocarcinoma cells through inhibition of Smad signalling: implications for in vivo mode of action

(2015) Tobias Bartscht et al.   Molecular Cancer

Gene expression changes reflect clinical response in a placebo-controlled randomized trial of abatacept in patients with diffuse cutaneous systemic sclerosis

(2015) Eliza F. Chakravarty et al.   ARTHRITIS RESEARCH & THERAPY

Nilotinib (Tasigna™) in the treatment of early diffuse systemic sclerosis: an open-label, pilot clinical trial

(2015) Jessica K. Gordon et al.   ARTHRITIS RESEARCH & THERAPY

Systems Level Analysis of Systemic Sclerosis Shows a Network of Immune and Profibrotic Pathways Connected with Genetic Polymorphisms

(2015) J. Matthew Mahoney et al.   PLoS Computational Biology

Editorial: Genomic Advances in Systemic Sclerosis: It Is Time for Precision

(2015) John Varga et al.   Arthritis & Rheumatology

CT staging and monitoring of fibrotic interstitial lung diseases in clinical practice and treatment trials: a Position Paper from the Fleischner society

(2015) David M Hansell et al.   Lancet Respiratory Medicine

The Molecular Signatures Database Hallmark Gene Set Collection

(2015) Arthur Liberzon et al.   Cell Systems

Systemic sclerosis

(2015) Yannick Allanore et al.   Nature Reviews Disease Primers

Review: Interstitial Lung Disease Associated With Systemic Sclerosis and Idiopathic Pulmonary Fibrosis: How Similar and Distinct?

(2014) Erica L. Herzog et al.   Arthritis & Rheumatology

Current status of systemic sclerosis biomarkers: applications for diagnosis, management and drug development

(2013) Flavia V Castelino et al.   Expert Review of Clinical Immunology

Molecular Signatures in Skin Associated with Clinical Improvement during Mycophenolate Treatment in Systemic Sclerosis

(2013) Monique Hinchcliff et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Tyrosine kinase signaling in fibrotic disorders

(2012) Christian Beyer et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

Adiponectin: mechanistic insights and clinical implications

(2012) A. T. Turer et al.   DIABETOLOGIA

Intrinsic Gene Expression Subsets of Diffuse Cutaneous Systemic Sclerosis Are Stable in Serial Skin Biopsies

(2012) Sarah A. Pendergrass et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Suppression of PDGF-induced PI3 kinase activity by imatinib promotes adipogenesis and adiponectin secretion

(2012) Stephen Fitter et al.   JOURNAL OF MOLECULAR ENDOCRINOLOGY

Levels of adiponectin, a marker for PPAR-gamma activity, correlate with skin fibrosis in systemic sclerosis: potential utility as a biomarker?

(2012) Katja Lakota et al.   ARTHRITIS RESEARCH & THERAPY

Quantitative texture-based assessment of one-year changes in fibrotic reticular patterns on HRCT in scleroderma lung disease treated with oral cyclophosphamide

(2011) Hyun J. Kim et al.   EUROPEAN RADIOLOGY

Scleroderma: from pathophysiology to novel therapeutic approaches

(2010) Nicolas Hunzelmann et al.   EXPERIMENTAL DERMATOLOGY

Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib

(2010) N. P. Shah et al.   HAEMATOLOGICA

Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

(2010) Hagop Kantarjian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Reproducibility of Lung and Lobar Volume Measurements Using Computed Tomography

(2009) Matthew S. Brown et al.   ACADEMIC RADIOLOGY

Treatment of Scleroderma-Interstitial Lung Disease With Cyclophosphamide Is Associated With Less Progressive Fibrosis on Serial Thoracic High-Resolution CT Scan Than Placebo

(2009) Jonathan Goldin et al.   CHEST

Surfactant Protein D and KL-6 as Serum Biomarkers of Interstitial Lung Disease in Patients with Scleroderma

(2009) F. N. HANT et al.   JOURNAL OF RHEUMATOLOGY

Transforming growth factor β as a therapeutic target in systemic sclerosis

(2009) John Varga et al.   Nature Reviews Rheumatology

A non-Smad mechanism of fibroblast activation by transforming growth factor-β via c-Abl and Egr-1: selective modulation by imatinib mesylate

(2009) S Bhattacharyya et al.   ONCOGENE

Classification of Parenchymal Abnormality in Scleroderma Lung Using a Novel Approach to Denoise Images Collected via a Multicenter Study

(2008) Hyun J. Kim et al.   ACADEMIC RADIOLOGY

Interstitial Lung Disease in Systemic Sclerosis

(2008) Nicole S. L. Goh et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Src kinases in systemic sclerosis: Central roles in fibroblast activation and in skin fibrosis

(2008) Catherine Skhirtladze et al.   ARTHRITIS AND RHEUMATISM

Profound Inhibition of Antigen-Specific T-Cell Effector Functions by Dasatinib

(2008) R. Weichsel et al.   CLINICAL CANCER RESEARCH

The Src/ABL kinase inhibitor dasatinib (BMS-354825) inhibits function of normal human T-lymphocytes in vitro

(2008) Stephen Blake et al.   CLINICAL IMMUNOLOGY

Metabolism and Disposition of Dasatinib after Oral Administration to Humans

(2008) L. J. Christopher et al.   DRUG METABOLISM AND DISPOSITION

Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis

(2008) Alfiya Akhmetshina et al.   FASEB JOURNAL

Intermittent Target Inhibition With Dasatinib 100 mg Once Daily Preserves Efficacy and Improves Tolerability in Imatinib-Resistant and -Intolerant Chronic-Phase Chronic Myeloid Leukemia

(2008) Neil P. Shah et al.   JOURNAL OF CLINICAL ONCOLOGY

Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib

(2008) A Hochhaus et al.   LEUKEMIA

Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib

(2008) Oliver Hantschel et al.   LEUKEMIA & LYMPHOMA

Molecular Subsets in the Gene Expression Signatures of Scleroderma Skin

(2008) Ausra Milano et al.   PLoS One